Literature DB >> 12475221

Suppression of interleukin-1 beta-induced nitric oxide production in RINm5F cells by inhibition of glucose-6-phosphate dehydrogenase.

Li Guo1, Zhiquan Zhang, Katherine Green, Robert C Stanton.   

Abstract

In rat pancreatic islets and insulin-producing cell lines, IL-1beta induces expression of inducible nitric oxide synthase and NO production leading to impairment of glucose-stimulated insulin release and decreased cell survival. NADPH is an obligatory cosubstrate for iNOS synthesis of NO. We hypothesized that IL-1beta stimulates an increase in activity of NADPH-producing enzyme(s) prior to NO production and that this increase is necessary for NO production. Using rat insulin-secreting RINm5F cells, we found that (1) IL-1beta caused a biphasic change in the NADPH level (increased by 6 h and decreased after prolonged incubation in the presence of 2 ng/mL IL-1beta); (2) IL-1beta stimulated increased activity of glucose-6-phosphate dehydrogenase (G6PD) in a time- and dose-dependent manner, and G6PD expression was increased by about 80% after exposure to 2 ng/mL IL-1beta for 18 h: (3) IL-1beta-stimulated NO production was positively correlated with increased G6PD activity; (4) IL-1beta did not cause any significant change in enzyme activity of another NADPH-producing enzyme, malic enzyme; (5) IL-1beta-induced NO production was significantly reduced either by inhibiting G6PD activity using an inhibitor of G6PD (dehydroepiandrosterone) or by inhibiting G6PD expression using an antisense oligonucleotide to G6PD mRNA; and (6) IL-1beta stimulated a decrease in the cAMP level. 8-Bromo-cAMP caused decreased G6PD activity, and the protein kinase A inhibitor H89 led to a increase in G6PD activity in RINm5F cells. In conclusion, our data show that IL-1beta stimulated G6PD activity and expression level, providing NADPH that is required by iNOS for NO production in RINm5F cells. Also, inhibition of the cAMP-dependent PKA signal pathway is involved in an IL-1beta-stimulated increase in G6PD activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12475221     DOI: 10.1021/bi026110v

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity.

Authors:  Jane A Leopold; Aamir Dam; Bradley A Maron; Anne W Scribner; Ronglih Liao; Diane E Handy; Robert C Stanton; Bertram Pitt; Joseph Loscalzo
Journal:  Nat Med       Date:  2007-02-04       Impact factor: 53.440

2.  Characterization of a cyclophosphamide-induced murine model of immunosuppression to study Acinetobacter baumannii pathogenesis.

Authors:  Swetha Manepalli; Jay A Gandhi; Vaibhav V Ekhar; Melissa B Asplund; Carolina Coelho; Luis R Martinez
Journal:  J Med Microbiol       Date:  2013-09-02       Impact factor: 2.472

3.  pO(2)-dependent NO production determines OPPC activity in macrophages.

Authors:  Mary A Robinson; Stephen W Tuttle; Cynthia M Otto; Cameron J Koch
Journal:  Free Radic Biol Med       Date:  2009-10-12       Impact factor: 7.376

4.  Macrophage glucose-6-phosphate dehydrogenase stimulates proinflammatory responses with oxidative stress.

Authors:  Mira Ham; Joo-Won Lee; A Hyun Choi; Hagoon Jang; Goun Choi; Jiyoung Park; Chisayo Kozuka; Dorothy D Sears; Hiroaki Masuzaki; Jae Bum Kim
Journal:  Mol Cell Biol       Date:  2013-04-09       Impact factor: 4.272

5.  The role of nitric oxide synthase in post-operative hyperglycaemia.

Authors:  Ss Qader
Journal:  Libyan J Med       Date:  2008-09-01       Impact factor: 1.657

6.  G6PD deficiency, redox homeostasis, and viral infections: implications for SARS-CoV-2 (COVID-19).

Authors:  Hung-Chi Yang; Tian-Hsiang Ma; Wen-Ye Tjong; Arnold Stern; Daniel Tsun-Yee Chiu
Journal:  Free Radic Res       Date:  2021-01-06

Review 7.  The Redox Role of G6PD in Cell Growth, Cell Death, and Cancer.

Authors:  Hung-Chi Yang; Yi-Hsuan Wu; Wei-Chen Yen; Hui-Ya Liu; Tsong-Long Hwang; Arnold Stern; Daniel Tsun-Yee Chiu
Journal:  Cells       Date:  2019-09-08       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.